Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1

Journal of Molecular Biology

Volumn 368, Issue 3, 2007, Pages 767-779

  Matsumiya, Shigeki ^a   Yamaguchi, Yoshiki ^b   Saito, Jun ichi ^a   Nagano, Mayumi ^b   Sasakawa, Hiroaki ^c   Otaki, Shizuo ^a   Satoh, Mitsuo ^a   Shitara, Kenya ^a   Kato, Koichi ^b,c,d  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c INSTITUTE FOR MOLECULAR SCIENCE   (Japan)

^d GLYENCE Co Ltd   (Japan)

Author keywords

antibody dependent cellular cytotoxicity; fucose; immunoglobulin G1; NMR spectroscopy; X ray crystal structure analysis

Indexed keywords

ASPARAGINE; ASPARTIC ACID; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; COMPARATIVE STUDY; CONFORMATION; CRYSTAL STRUCTURE; FUCOSYLATION; HYDRATION; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

EID: 34047142084     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.02.034     Document Type: Article

References (58)

1. Burton D.R., and Woof J.M. Human antibody effector function. Adv. Immunol. 51 (1992) 1-84
2. Jefferis R., Lund J., and Pound J.D. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol. Rev. 163 (1998) 59-76
3. Parekh R.B., Dwek R.A., Sutton B.J., Fernandes D.L., Leung A., Stanworth D., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316 (1985) 452-457
4. Mizuochi T., Hamako J., and Titani K. Structures of the sugar chains of mouse immunoglobulin G. Arch. Biochem. Biophys. 257 (1987) 387-394
5. Takahashi N., Ishii I., Ishihara H., Mori M., Tejima S., Jefferis R., et al. Comparative structural study of the N-linked oligosaccharides of human normal and pathological immunoglobulin G. Biochemistry 26 (1987) 1137-1144
6. Parekh R., Roitt I., Isenberg D., Dwek R., and Rademacher T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J. Exp. Med. 167 (1988) 1731-1736
7. Rothman R.J., Warren L., Vliegenthart J.F.G., and Härd K.J. Clonal analysis of the glycosylation of immunoglobulin G secreted by murine hybridomas. Biochemistry 28 (1989) 1377-1384
8. Mizuochi T., Hamako J., Nose M., and Titani K. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice. J. Immunol. 145 (1990) 1794-1798
9. Nakao H., Nishikawa A., Nishiura T., Kanayama Y., Tarui S., and Taniguchi N. Hypogalactosylation of immunoglobulin G sugar chains and elevated serum interleukin 6 in Castleman's disease. Clin. Chim. Acta 197 (1991) 221-228
10. Lund J., Takahashi N., Hindley S., Tyler R., Goodall M., and Jefferis R. Glycosylation of human IgG subclass and mouse IgG2b heavy chains secreted by mouse J558L transfectoma cell lines as chimeric antibodies. Hum. Antibodies Hybridomas 4 (1993) 20-25
11. Lund J., Takahashi N., Nakagawa H., Goodall M., Bentley T., Hindley S.A., et al. Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs. Mol. Immunol. 30 (1993) 741-748
12. Rademacher T.W., Williams P., and Dwek R.A. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc. Natl Acad. Sci. USA 91 (1994) 6123-6127
13. Youings A., Chang S.-C., Dwek R.A., and Scragg I.G. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem. J. 314 (1996) 621-630
14. Davies J., Jiang L., Pan L.-Z., LaBarre M.J., Anderson D., and Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. Biotechnol. Bioeng. 74 (2001) 288-294
15. Umaña P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnol. 17 (1999) 176-180
16. Kumpel B.M., Wang Y., Griffiths H.L., Hadley A.G., and Rook G.A. The biological activity of human monoclonal IgG anti-D is reduced by β-galactosidase treatment. Hum. Antibodies Hybridomas 6 (1995) 82-88
17. Kumpel B.M., Rademacher T.W., Rook G.A., Williams P.J., and Wilson I.B. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum. Antibodies Hybridomas 5 (1994) 143-151
18. Mimura Y., Sondermann P., Ghirlando R., Lund J., Young S.P., Goodall M., et al. Role of oligosaccharide residues of IgG1-Fc in FcγRIIb binding. J. Biol. Chem. 276 (2001) 45539-45547
19. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
20. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002) 26733-26740
21. Niwa R., Hatanaka S., Shoji-Hosaka E., Sakurada M., Kobayashi Y., Uehara A., et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcγRIIIa functional polymorphism. Clin. Caner Res. 10 (2004) 6248-6255
22. Niwa R., Shoji-Hosaka E., Sakurada M., Shinkawa T., Uchida K., Nakamura K., et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64 (2004) 2127-2133
23. Okazaki A., Shoji-Hosaka E., Nakamura K., Wakitani M., Uchida K., Kakita S., et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J. Mol. Biol. 336 (2004) 1239-1249
24. Natsume A., Wakitani M., Yamane-Ohnuki N., Shoji-Hosaka E., Niwa R., Uchida K., et al. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J. Immunol. Methods 306 (2005) 93-103
25. Niwa R., Sakurada M., Kobayashi Y., Uehara A., Matsushima K., Ueda R., et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin. Cancer Res. 11 (2005) 2327-2336
26. 297-linked oligosaccharides. J. Immunol. Methods 306 (2005) 151-160
27. Satoh M., Shitara K., and Hanai N. The current stream and prospect of glycoscience application-Therapeutic antibodies. Trends. Glycosci. Glycotech. 18 (2006) 129-136
28. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 20 (1981) 2361-2370
29. Sondermann P., Huber R., Oosthuizen V., and Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 406 (2000) 267-273
30. Radaev S., Motyka S., Fridman W.-H., Sautès-Fridman C., and Sun P.D. The structure of a human type III Fcγ receptor in complex with Fc. J. Biol. Chem. 276 (2001) 16469-16477
31. Radaev S., and Sun P. Recognition of immunoglobulins by Fcγ receptors. Mol. Immunol. 38 (2001) 1073-1083
32. Krapp S., Mimura Y., Jefferis R., Huber R., and Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325 (2003) 979-989
33. Yamaguchi Y., Nishimura M., Nagano M., Yagi H., Sasakawa K., Uchida K., et al. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim. Biophys. Acta General Subjects 1760 (2006) 693-700
34. Deisenhofer J., Colman P.M., Epp O., and Huber R. Crystallographic structural studies of a human Fc fragment. II. A complete model based on a Fourier map at 3.5 Å resolution. Hoppe-Seyler's Z Physiol. Chem. 357 (1976) 1421-1434
35. Idusogie E.E., Presta L.G., Gazzano-Santoro H., Totpal K., Wong P.Y., Ultsch M., et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164 (2000) 4178-4184
36. DeLano W.L., Ultsch M.H., de Vos A.M., and Wells J.A. Convergent solutions to binding at a protein-protein interface. Science 287 (2000) 1279-1283
37. Kleywegt G.J., Harris M.R., Zou J., Taylor T.C., Wählby A., and Jones T.A. The Uppsala Electron-Density Server. Acta Crystallog. sect. D 60 (2004) 2240-2249
38. Corper A.L., Sohi M.K., Bonagura V.R., Steinitz M., Jefferis R., Feinstein A., et al. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nature Struct. Biol. 4 (1997) 374-381
39. Sauer-Eriksson A.E., Kleywegt G.J., Uhlèn M., and Jones T.A. Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure 3 (1995) 265-278
40. Saphire E.O., Parren P.W.H.I., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293 (2001) 1155-1159
41. Martin W.L., West Jr. A.P., Gan L., and Bjorkman P.J. Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell 7 (2001) 867-877
42. Sprague E.R., Wang C., Baker D., and Bjorkman P.J. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS. Biol. 4 (2006) e148
43. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., et al. The Protein Data Bank. Nucl. Acids Res. 28 (2000) 235-242
44. Edberg J.C., and Kimberly R.P. Cell type-specific glycoforms of FcγRIIIa (CD16): differential ligand binding. J. Immunol. 159 (1997) 3849-3857
45. Ferrara C., Stuart F., Sondermann P., Brünker P., and Umaña P. The carbohydrate at FcγRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281 (2006) 5032-5036
46. Urlaub G., Mitchell P.J., Kas E., Chasin L.A., Funanage V.L., Myoda T.T., et al. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somat. Cell Mol. Genet. 12 (1986) 555-566
47. Yabe N., Matsuya Y., Yamane I., and Takada M. Enhanced formation of mouse hybridomas without hat treatment in a serum-free medium. In Vitro Cell Dev. Biol. 22 (1986) 363-368
48. 13C]methionine. Biochemistry 30 (1991) 270-278
49. Yamaguchi Y., and Kato K. Structural glycobiology by stable-isotope-assisted NMR spectroscopy. In: Webb G.A. (Ed). Modern Magnetic Resonance Vol. 2 (2006), Springer, Heidelberg 219-225
50. Yamaguchi Y., Kim H., Kato K., Masuda K., Shimada I., and Arata Y. Proteolytic fragmentation with high specificity of mouse immunoglobulin G. Mapping of proteolytic cleavage sites in the hinge region. J. Immunol. Methods 181 (1995) 259-267
51. Lund J., Tanaka T., Takahashi N., Sarmay G., Arata Y., and Jefferis R. A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation. Mol. Immunol. 27 (1990) 1145-1153
52. Papac D.I., Briggs J.B., Chin E.T., and Jones A.J. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis. Glycobiology 8 (1998) 445-454
53. Collaborative Computational Project, No. 4. The CCP4 suite: programs for protein crystallography. Acta Crytallog. sect. D 50 (1994) 760-763
54. McCoy A.J., Grosse-Kunstleve R.W., Storoni L.C., and Read R.J. Likelihood-enhanced fast translation functions. Acta Crytallog. sect. D 61 (2005) 458-464
55. Jones T.A., Zou J.-Y., Cowan S.W., and Kjeldgaard. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. A 47 (1991) 110-119
56. Winn M.D., Isupov M.N., and Murshudov G.N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crytallog. sect. D 57 (2001) 122-133
57. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26 (1993) 283-291
58. Bernstein H.J. Recent changes to RasMol, recombining the variants. Trends Biochem. Sci. 25 (2000) 453-455